Daryl Drummond

Daryl has 30 years of experience in the research and development of liposomal and lipidic nanoparticle (LNP) based therapeutics and vaccines. Daryl is currently the Founder, Chief Scientific Officer, and Senior Vice President of Akagera Medicines. At Akagera, he is advancing the use of sophisticated lipid-based nanotechnologies to deliver novel and highly potent anti-bacterial agents directly to innate immune cell reservoirs for mycobacterium or gram-positive bacterium and mRNA vaccines, targeting some of the world’s most challenging and neglected infectious diseases. Daryl also joined Tidal Therapeutics in 2019 as an SAB member and Interim CSO, prior to being acquired by Sanofi in 2021, where he oversaw the engineering and pharmacology of immune cell-targeted mRNA LNPs.

Dr. Drummond was a principal inventor for a wide range of nanotechnology-based drugs and platform technologies, most notably Onivyde, a highly stabilized liposomal formulation of irinotecan that was approved for the treatment of metastatic pancreatic cancer. Through June of 2019, Dr. Drummond served as the Head of Research and Senior Vice President of Discovery for Merrimack Pharmaceuticals. Overall, Dr. Drummond has more than 30 years of experience in the research and development of advanced drug delivery systems, including six unique drugs or imaging agents that have been tested in various clinical trials, an NDA and EMA approval for Onivyde, >50 issued patents or patent applications, and more than 75 peer reviewed publications.